Publication | Closed Access

The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment

Cancer ImmunosurveillanceMedicineTumor BurdenImmunologyImmune-checkpoint Inhibitor TreatmentImmune Checkpoint InhibitorImmunotherapyOncologyRadiation OncologyLung Cancer